Picture of Mauna Kea Technologies SA logo

ALMKT — Mauna Kea Technologies SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Brief: Mauna Kea Technologies Receives U.S. FDA Clearance Of Its Next-Generation Cellvizio® Platform

Aug 24 (Reuters) - Mauna Kea Technologies SAS  MKEA.PA :
    * MAUNA KEA TECHNOLOGIES RECEIVES U.S. FDA 510(K) CLEARANCE
OF ITS
NEXT-GENERATION CELLVIZIO® PLATFORM COMBINED WITH A FLUORESCENT
CONTRAST AGENT
    * NEXT-GENERATION CELLVIZIO® PLATFORM IS NOW CLEARED FOR USE
WITH
FLUORESCEIN DYE TO IMAGE BLOOD FLOW IN MICROVASCULATURE AND
CAPILLARIES AS A COMBINATION DRUG-DEVICE

Source text for Eikon:  ID:nBw8xMvxQa 
Further company coverage:  MKEA.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))

Recent news on Mauna Kea Technologies SA

See all news